POSTER SESSIONS ABSTRACTS
Poster Session XV
P-15
PHARMACOGENETICS, PHARMACOGENOMICS AND GENE THERAPY, INNOVATIVE AND
BIOTECHNOLOGICAL DRUGS, DRUG INFORMATION
| P-15/1 | Clinical application
of pharmacogenetics of DPYD to the diagnosis of toxicity induced by
fluoropyrimidines M. Del Re, F. Loupakis, A. Michelucci , A. Di Paolo, A. Falcone, P. Simi, G. Bocci, M. Cantore, R. Bordonaro, A. Di Leo, C. Barbara, F. Cappuzzo, F. De Braud, R. Danesi (Pisa, Carrara, Catania, Prato, Livorno, Milano) |
| P-15/2 | Polymorphisms of glutathione S-transferase (GST-M1 and GST-T1)
and relapse in childhood Acute Lymphoblastic Leukemia (ALL) R. Franca, E. Cuzzoni, A. Zanut, P. Rebora, S. De Iudicibus, G. Decorti, MG. Valsecchi, M. Rabusin (Trieste, Monxa, Monza) |
| P-15/3 | Validation and implementation into
routine clinical practice of a novel HLA-B*57:01 screening test for the
prevention of abacavir hypersensitivity. C. Dello Russo, L. Lisi, S. Di Giambenedetto , R. Cauda , P. Navarra (Roma) |
| P-15/4 | Involvement of the mu-opioid
receptor gene polymorphism A118G in alcohol dependent patients. V. Marini, C. Fucile, ML. Zuccoli, D. Barciocco, L. Robbiano, F. Mattioli, A. Martelli (Genova) |
| P-15/5 | Pharmacogenetic determinants of imatinib, dasatinib and nilotinib
pharmacokinetics in chronic myeloid leukaemia patients. A. Ariaudo, S. De Francia, A. D\'Avolio, E. Pirro, FM. Piccione, M. Simiele, C. Fava, G. Saglio, F. Di Carlo (Torino) |
| P-15/6 | Pharmacogenetic determinants of
mitotane pharmacokinetics in adrenocortical cancer patients. F. De Martino, S. De Francia, A. D\'Avolio, E. Pirro, FM. Piccione, J. Jessica, A. Alfredo, M. Massimo, F. Francesco (Torino) |
| P-15/7 | Prospective validation of a
genetic-based algorithm for warfarin dosing. An ad interim analysis F. Groppa, A. Rossetto, V. Pengo, CF. Zambon, G. De Rosa, M. Pelloso, P. Fogar, M. Gusella, M. Plebani, R. Padrini (Padova, Rovigo) |
| P-15/8 | Role of EZH2 SNPs
in metastatic Colorectal Cancer (mCRC) patients
treated with FOLFIRI regimen E. Paolicchi, F. Crea , L. Fornaro, G. Masi, P. Frumento, F. Loupakis, L. Salvatore, C. Cremolini, M. Schirripa, F. Graziano, M. Ronzoni, V. Ricci, WL. Farrar, A. Falcone, R. Danesi (Pisa, Pesaro, Milano, Frederick) |
| P-15/9 | Pharmacogeneticsof
ranibizumab in patients with age-related macular degeneration B. Canu, S. Lazzeri, P. Orlandi, E. Agosta, A. Fioravanti, T. Di Desidero, M. Figus, M. Nardi, R. Danesi, G. Bocci (Pisa) |
| P-15/10 | Peroxisome
proliferators activated receptors gamma and the inflammatory state of gastric mucosa A. Sapone, S. Melega, D. Canistro, L. Gatta, D. Vaira, D. Ranieri, A. Ieronimo, M. Paolini (Bologna) |
| P-15/11 | The molecular composition, biophysical properties and drug
responses of BK channels of slow and fast-twitch skeletal muscles are
phenotype dependent M.M. Dinardo, G.M. Camerino, A. Mele, G. Cannone, R. Latorre, D. Conte Camerino, D. Tricarico (Bari, Valparaiso (Chile)) |
| P-15/12 | VEGF-A polymorphisms are
associated with clinical response and progression free survival in advanced
hormone-refractory prostate cancer patients treated with a metronomic
cyclophosphamide, dexamethasone and celecoxib schedule. P. Orlandi, A. Fontana, A. Fioravanti, B. Canu, T. Di Desidero, L. Galli, L. De Rosa, A. Falcone, R. Danesi, G. Bocci (Pisa) |
| P-15/13 | Correlation between BclI polymorphism in the NR3C1 gene
and individual variations in lymphocyte-responses to glucocorticoids S. De Iudicibus, E. Cuzzoni, F. Bartoli, A. Ventura, G. Decorti (Trieste) |
| P-15/14 | Role of genetic polymorphisms of enzymes involved in azathioprine
activation and correlation with blood metabolite concentrations in pediatric
patientswith IBD E. Cuzzoni, S. De Iudicibus, G. Stocco, R. Franca, F. Bartoli, S. Martelossi, A. Ventura, G. Decorti (Trieste) |
| P-15/15 | Clinical implications of MTHFR C677T polymorphism in
cardiovascular diseases S. Magi, P. Castaldo, G.P. Perna, M. Marini, M. Francioni, A.A. Nasti, G. Galeazzi, C.A. Violet, S. Amoroso (Ancona) |
| P-15/16 | Radiogenetics and the outcome of radiation-treated prostate cancer
patients C. Zanusso, E. Cecchin, R. Bortolus, P. Biason, E. De Mattia, S. Boffo, M.G. Trovò, G. Toffoli (Aviano (PN)) |
| P-15/17 | Investigation on MTHFR, DYPD and
TSER polymorphisms in 5-Fluorouracil toxicity: a case report A. Scalvini, V. Ferrari, G. Arcangeli, F. Consoli, PF. Spano, S. Sigala, S. Bodei ( |
| P-15/18 | Genome-wide identification of
determinants of leukemia cell sensitivity to mercaptopurine G. Stocco, W. Yang, K. Crews, W. Thierfelder, S. Paugh, B. Diouf, R. Mc Corkle, M. Den Boer, M. Relling, R. Pieters, W. Evans (Trieste, Memphis, Rotterdam) |
| P-15/19 | Genetic polymorphisms in the early onset of oxaliplatin
neuropathy after adjuvant FOLFOX E. Cecchin, C. Zanusso, M. D\'Andrea, N. Pella, D. Errante, S. Bonura, M. Bari, M. Medici, A. Buonadonna, P. Biason, E. De Mattia, S. Boffo, G. Toffoli (Aviano, Roma, Udine, Conegliano, Latisana, Noale, Mestre) |
| P-15/20 | Pharmacogenetic
of Warfarin: study on a population of Campania Region V. Simeon, V. Conti, R. Russomanno, V. Paribello, C. Mazzaccara, M.R. Lupone, A. Cottarelli, L. Sacchetti, C. Perricone, A. Filippelli (Napoli) |
| P-15/21 | Influence of GRIK4 and GNB3 polymorphisms on
diagnosis and treatment outcome in major depression disorders C. Crisafulli, M. Calabrò, E. Spina, A. Chiesa, I. Massat, S. Linotte, R. Calati, S. Kasper, U. Bailer, Y. Lecrubier, M. Fink, I. Antonijevic, C. Forray, L. Snyder, J. Bollen, J. Zohar, D. De Ronchi, D. Souery, J. Mendlewicz, A. Serretti (Messina, Bologna, Bruxelles, Vienna, Paris, U.S.A., Sint-Truiden, Israel) |
| P-15/22 | Genetic determinants of severe gastrointestinal toxicity during
therapy with 6-mercaptopurine and methotrexate in pediatric acute
lymphoblastic leukemia G. Stocco, W. Yang, K.R. Crews, W.E. Thierfelder, S.P. Paugh, B. Diouf, J.R. McCorkle, G. Decorti, M. Londero, R. Franca, M.G. Valsecchi, M. Rabusin, M.V. Relling, C-H. Pui, W.E. Evans (Trieste, Memphis, Milano) |
| P-15/23 | miRNA-dependent regulation of
ABCG2 in imatinib resistant K-562 cells E. Turrini, S. Haenisch, S. Laechelt, O. Brhun, P. Hrelia, I. Cascorbi (Bologna, Kiel) |
| P-15/24 | NCX 434, a novel nitric oxide (NO)-donating triamcinolone
acetonide analog shows long lasting activity in the VEGF-induced leakage
model of diabetic macular edema in rabbits F. Impagnatiello, C. De Nardi, S. Brambilla, V. Chiroli, A.H. Krauss, G. Prasanna, E. Ongini (Milano, USA) |
| P-15/25 | Ocular hypotensive effects of NCX 139, a nitric oxide
(NO)-donating latanoprost amide, in normotensive and ocular hypertensive
rabbits and dogs F. Impagnatiello, V. Borghi, F. Benedini, S.T. Carreiro, W.KM. Chong, G. Prasanna, A.H. Krauss, E. Ongini (Milan, USA) |
| P-15/26 | Reversine
increases plasticity of human Mesenchymal Stem Cells E. Arrigoni, E. Conforti , S. Niada , D. Stanco , M. Piccoli, L. de Girolamo , L. Anastasia , A.T. Brini (Milano) |
| P-15/27 | Non-viral
HPMA-oligolysine copolymers for improved siRNA delivery to neuron-like cells G. Carbonari, R. Johnson, S.H. Pun, S. Spampinato (Bologna, Seattle) |
| P-15/28 | Human adipose-derived stem cells (hASCs) from obese patients and
their feasible use in cell-based therapies D. Stanco, E. Arrigoni, L. De Girolamo, L. Salvatori, N. Niada, V. Yenagi, E. Petrangeli, A. Brini (Milano, Roma) |
| P-15/29 | Independent information on drug
efficacy and safety: 2009-2011 experience of the "SIF-Farmaci in Evidenza"
newsletter M.A. Catania, M.R. Luppino, A.C .Rosa, S. Sigala, F. Casale, R. Fantozzi, SIF-Farmaci in Evidenza Network (Messina, Torino, Brescia, Milano) |
| P-15/30 | Drug
Information Service: an informative campaign on “Drugs and G6PD deficiency” P. Carta, A. Deidda, M.E. Stochino, E. Mosca, M. Del Zompo (Cagliari) |
| P-15/31 | Information
campaign and management of an independent website on drugs P. Carta, F. Ligas, C. Asuni, M.E. Stochino, V. Deiana, E. Mosca, C. Chillotti, M. Del Zompo (Cagliari) |
| P-15/32 | Consultancy Pharmacology as an
activity of an Independent Service of Information and Formation on Medicine. F. Ligas, A. Deidda, V. Deiana, M. Pinna, M.E. Stochino , M. Del Zompo, R. Ardau (Cagliari) |
| P-15/33 | Piperacillin/tazobactam: what will
the future be like? A. Tomaino, M. Cristani, T. Arcoraci, M. Martorana (Messina) |